Adherence to extended release tolterodine versus immediate- and extended-release oxybutynin among commercially-insured patients with overactive bladder

被引：0
|
作者：
Ollendorf, DA
Jumadilova, Z
Varadharajan, S
Girase, P
机构：
[1] Pharmetrics, Watertown, MA USA
[2] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)63137-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：416 / 416
页数：1
相关论文
共 50 条
  • [31] Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder
    Ginsberg, David
    Schneider, Tim
    Kelleher, Con
    Van Kerrebroeck, Philip
    Swift, Steven
    Creanga, Dana
    Martire, Diane L.
    BJU INTERNATIONAL, 2013, 112 (03) : 373 - 385
  • [32] Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin
    Sathyan, G
    Dmochowski, RR
    Appel, RA
    Guo, C
    Gupta, SK
    CLINICAL PHARMACOKINETICS, 2004, 43 (14) : 1059 - 1068
  • [33] Comparison of gastrointestinal effects with extended-release formulations of oxybutynin and tolterodine
    Peters, KM
    JOURNAL OF UROLOGY, 2004, 171 (04): : 136 - 136
  • [34] Effect of Antacid on the Pharmacokinetics of Extended-Release Formulations of Tolterodine and Oxybutynin
    Gayatri Sathyan
    Roger R. Dmochowski
    Rodney A. Appell
    Cindy Guo
    Suneel K. Gupta
    Clinical Pharmacokinetics, 2004, 43 : 1059 - 1068
  • [35] Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: The antimuscarinic clinical effectiveness trial (ACET)
    Sussman, D
    Garely, A
    CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) : 177 - 184
  • [36] The Abuse Potential of Remoxy®, an Extended-Release Formulation of Oxycodone, Compared with Immediate- and Extended-Release Oxycodone
    Setnik, Beatrice
    Roland, Carl L.
    Cleveland, Jody M.
    Webster, Lynn
    PAIN MEDICINE, 2011, 12 (04) : 618 - 631
  • [37] Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder
    Kelleher, CJ
    Reese, PR
    Pleil, AM
    Okano, GJ
    AMERICAN JOURNAL OF MANAGED CARE, 2002, 8 (19): : S608 - S615
  • [38] COST-EFFECTIVENESS OF PERCUTANEOUS TIBIAL NERVE STIMULATION VERSUS EXTENDED-RELEASE TOLTERODINE FOR OVERACTIVE BLADDER
    Chen, Heidi
    Bercik, Richard
    Thung, Stephen
    NEUROUROLOGY AND URODYNAMICS, 2011, 30 (02) : 247 - 247
  • [39] Cognitive effects of Immediate Release and extended-release oxybutynin in an elderly population
    Sand, Peter K.
    Modi, Nishit B.
    Gupta, Suneel
    OBSTETRICS AND GYNECOLOGY, 2006, 107 (04): : 4S - 4S
  • [40] Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan
    D'Souza, Anna O.
    Smith, Michael J.
    Miller, Lesley-Ann
    Doyle, Joseph
    Ariely, Rinat
    JOURNAL OF MANAGED CARE PHARMACY, 2008, 14 (03): : 291 - 301
12345